title: Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.
abstract: Human kidney injury molecule-1 (hKIM-1) is a type 1 transmembrane protein that is not detectable in normal kidney tissue but is expressed at high levels in human and rodent kidneys with dedifferentiated proximal tubule epithelial cells after ischemic or toxic injury. Therefore, it was hypothesized that renal tumors express hKIM-1 and release this protein into the urine. Forty renal cell carcinoma (RCC) and 484 nonrenal tumors were analyzed by immunohistochemistry for expression of hKIM-1 (group 1). Urine samples before nephrectomy and nephrectomy tissue samples were collected from an additional 42 patients with renal tumors, from 30 normal control subjects, and also from 10 patients with prostate carcinoma (group 2). In five additional patients with RCC, urine was collected before and after nephrectomy (group 3). Tissue was examined for expression of hKIM-1, and cell-free urine supernatants were analyzed for hKIM-1 by ELISA. Urinary hKIM-1 was normalized to the urinary creatinine concentration (U(Cr)). Expression of hKIM-1 was present in 32 tissue sections (91%) of 35 clear cell RCC (group 1). In group 2, the normalized urinary hKIM-1 levels were significantly higher in patients with clear cell RCC (0.39 +/- 0.08 ng/mg U(Cr); n = 21), compared with levels in patients with prostate carcinoma (0.12 +/- 0.03 ng/mg U(Cr); P < 0.02; n = 10), or normal control subjects (0.05 +/- 0.01 ng/mg U(Cr); P < 0.005; n = 30). Tissue sections from 28 (82%) of 34 primary RCC stained positively for the expression of hKIM-1. In all patients with a detectable prenephrectomy urinary hKIM-1 level, there was either complete disappearance or marked reduction after nephrectomy (group 3). In conclusion, the cleaved ectodomain of hKIM-1 can be detected in the urine of patients with RCC and may serve as a new biomarker for early detection of RCC.
authors.affiliation: Renal Division, Brigham and Women's Hospital, Medical Service, Massachusetts General Hospital, Boston, USA.
authors.forename: Won K
authors.initials: WK
authors.lastname: Han
authors.forename: Anwar
authors.initials: A
authors.lastname: Alinani
authors.forename: Chin-Lee
authors.initials: CL
authors.lastname: Wu
authors.forename: Dror
authors.initials: D
authors.lastname: Michaelson
authors.forename: Massimo
authors.initials: M
authors.lastname: Loda
authors.forename: Francis J
authors.initials: FJ
authors.lastname: McGovern
authors.forename: Ravi
authors.initials: R
authors.lastname: Thadhani
authors.forename: Joseph V
authors.initials: JV
authors.lastname: Bonventre
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism / Q000652:urine; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000601:surgery / Q000652:urine; D016022:Case-Control Studies; D000072596:Hepatitis A Virus Cellular Receptor 1; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000601:surgery / Q000652:urine; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism* / Q000652:urine; D009392:Nephrectomy; D011184:Postoperative Period; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000652:urine; D011991:Receptors, Virus / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; C491143:HAVCR1 protein, human; D000072596:Hepatitis A Virus Cellular Receptor 1; D008562:Membrane Glycoproteins; D011991:Receptors, Virus
references.citation: Int J Cancer. 2000 Sep 1;87(5):650-3
references.pmid: 10925357
references.citation: Urology. 2000 Feb;55(2):227-30
references.pmid: 10688084
references.citation: Cancer Res. 2003 Dec 15;63(24):8695-9
references.pmid: 14695183
references.citation: Mod Pathol. 2000 Oct;13(10):1109-14
references.pmid: 11048805
references.citation: Med Pediatr Oncol. 2001 Oct;37(4):357-64
references.pmid: 11568899
references.citation: Am J Surg Pathol. 2001 Dec;25(12):1485-92
references.pmid: 11717537
references.citation: BJU Int. 2001 Dec;88(9):974-7
references.pmid: 11851623
references.citation: Br J Cancer. 2002 Jan 21;86(2):185-9
references.pmid: 11870503
references.citation: Br J Cancer. 2002 May 6;86(9):1396-400
references.pmid: 11986770
references.citation: Kidney Int. 2002 Jul;62(1):237-44
references.pmid: 12081583
references.citation: J Biol Chem. 2002 Oct 18;277(42):39739-48
references.pmid: 12138159
references.citation: Am J Physiol Renal Physiol. 2002 Dec;283(6):F1326-36
references.pmid: 12388382
references.citation: Pathol Oncol Res. 2002;8(4):241-4
references.pmid: 12579209
references.citation: J Urol. 2003 Apr;169(4):1530-4
references.pmid: 12629409
references.citation: Nat Rev Immunol. 2003 Jun;3(6):454-62
references.pmid: 12776205
references.citation: Urol Clin North Am. 2003 Aug;30(3):455-65
references.pmid: 12953748
references.citation: Cancer Treat Res. 2003;116:199-212
references.pmid: 14650834
references.citation: Am J Physiol Renal Physiol. 2004 Mar;286(3):F552-63
references.pmid: 14600030
references.citation: Springer Semin Immunopathol. 2004 Feb;25(3-4):335-48
references.pmid: 15007635
references.citation: J Urol. 2004 Jul;172(1):58-62
references.pmid: 15201737
references.citation: Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;48(3):207-17
references.pmid: 2859694
references.citation: Int J Cancer. 1986 Oct 15;38(4):489-94
references.pmid: 2428759
references.citation: Semin Nephrol. 1987 Jun;7(2):131-9
references.pmid: 3306862
references.citation: Cancer Res. 1989 Apr 1;49(7):1802-9
references.pmid: 2466563
references.citation: Am J Surg Pathol. 1995 Jul;19(7):842-9
references.pmid: 7540804
references.citation: Br J Urol. 1996 Apr;77(4):524-9
references.pmid: 8777611
references.citation: N Engl J Med. 1996 Sep 19;335(12):865-75
references.pmid: 8778606
references.citation: Br J Urol. 1996 Jul;78(1):29-32
references.pmid: 8795396
references.citation: Cancer. 1997 Sep 1;80(5):987-9
references.pmid: 9307203
references.citation: J Biol Chem. 1998 Feb 13;273(7):4135-42
references.pmid: 9461608
references.citation: Semin Diagn Pathol. 1998 Feb;15(1):54-67
references.pmid: 9503506
references.citation: J Virol. 1998 Jul;72(7):6218-22
references.pmid: 9621093
references.citation: J Virol. 1998 Aug;72(8):6621-8
references.pmid: 9658108
references.citation: Trends Genet. 1998 Oct;14(10):423-6
references.pmid: 9820032
references.citation: JAMA. 1999 May 5;281(17):1628-31
references.pmid: 10235157
references.citation: Cancer. 1999 Aug 1;86(3):492-7
references.pmid: 10430258
references.citation: Anticancer Res. 1999 Jul-Aug;19(4A):2583-90
references.pmid: 10470199
references.citation: J Urol. 1999 Oct;162(4):1246-58
references.pmid: 10492174
references.citation: J Urol. 1999 Oct;162(4):1277-81
references.pmid: 10492179
references.citation: Tumour Biol. 2001 Sep-Oct;22(5):282-5
references.pmid: 11553857
references.citation: J Urol. 2001 May;165(5):1710-3
references.pmid: 11342961
references.citation: Anticancer Res. 2000 Nov-Dec;20(6D):5095-8
references.pmid: 11326675
references.citation: Clin Cancer Res. 2001 Jan;7(1):89-92
references.pmid: 11205923
references.citation: Cancer Detect Prev. 2000;24(6):579-88
references.pmid: 11198272